The DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Drug resistance in ovarian cancer: from mechanism to clinical trial
Open accessAbstract
Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges for the treatment of drug-resistant ovarian cancer. Continuing to classify drug resistance according to drug type without understanding the underlying mechanisms is unsuitable for current clinical practice. We reviewed the literature regarding various drug resistance mechanisms in ovarian cancer and found that the main resistance mechanisms are as follows: abnormalities in transmembrane transport, alterations in DNA damage repair, dysregulation of cancer-associated signaling pathways, and epigenetic modifications. DNA methylation, histone modifications and noncoding RNA activity, three key classes of epigenetic modifications, constitute pivotal mechanisms of drug resistance. One drug can have multiple resistance mechanisms. Moreover, common chemotherapies and targeted drugs may have cross (overlapping) resistance mechanisms. MicroRNAs (miRNAs) can interfere with and thus regulate the abovementioned pathways. A subclass of miRNAs, “epi-miRNAs”, can modulate epigenetic regulators to impact therapeutic responses. Thus, we also reviewed the regulatory influence of miRNAs on resistance mechanisms. Moreover, we summarized recent phase I/II clinical trials of novel drugs for ovarian cancer based on the abovementioned resistance mechanisms. A multitude of new therapies are under evaluation, and the preliminary results are encouraging. This review provides new insight into the classification of drug resistance mechanisms in ovarian cancer and may facilitate in the successful treatment of resistant ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liu, H., Zhang, Y.-Y., Zhu, B.-L., Feng, F., Zhang, H.-T., Yan, H., & Zhou, B. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0532-2 · Cited by 50
RetractedTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Modular regulatory principles of large non-coding RNAs
Guttman, M., & Rinn, J. L. (2012) · Nature · doi:10.1038/nature10887 · Cited by 2,265
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961
MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship
Pasquinelli, A. E. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3162 · Cited by 1,593
Epigenetics: Regulation Through Repression
Wolffe, A. P., & Matzke, M. A. (1999) · Science · doi:10.1126/science.286.5439.481 · Cited by 1,239
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Bray, S. J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.94 · Cited by 1,012 · cited 1×
“Following proteolytic cleavage of Notch by γ-secretase (an instrumental proteolytic enzyme in the Notch pathway), the active NICD fragment is translocated to the nucleus, where it induces the transcription of Notch target genes through interaction with CSL transcriptional regulators [120].”
BackgroundTargeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Riballo, E., Kühne, M., Rief, N., Doherty, A., Smith, G. C. M., Recio, M.-J., Reis, C., Dahm, K., Fricke, A., Krempler, A., et al. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.029 · Cited by 837 · cited 1×
“DNA-PKcs plays a major role in promoting NHEJ through autophosphorylation and recruitment of downstream effectors, such as endonucleases (Artemis) [68] and polymerases (DNA POLM (Pol µ) and POLL (Pol λ)) [69, 70].”
BackgroundMetallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis
Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28574 · Cited by 703
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
The shieldin complex mediates 53BP1-dependent DNA repair
Noordermeer, S. M., Adam, S., Setiaputra, D., Barazas, M., Pettitt, S. J., Ling, A. K., Olivieri, M., Álvarez-Quilón, A., Moatti, N., Zimmermann, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0340-7 · Cited by 645
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Endoplasmic Reticulum Stress and the Hallmarks of Cancer
Urra, H., Dufey, E., Avril, T., Chevet, E., & Hetz, C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.03.007 · Cited by 615
Zhang, H., Liu, C.-Y., Zha, Z.-Y., Zhao, B., Yao, J., Zhao, S., Xiong, Y., Lei, Q.-Y., & Guan, K.-L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900843200 · Cited by 569
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Nagata, K., Ohashi, K., Nakano, T., Arita, H., Zong, C., Hanafusa, H., & Mizuno, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.47.30022 · Cited by 529
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01549 · Cited by 511
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
Zhang, L., Volinia, S., Bonome, T., Calin, G. A., Greshock, J., Yang, N., Liu, C.-G., Giannakakis, A., Alexiou, P., Hasegawa, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801615105 · Cited by 511
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Gupta, R., Somyajit, K., Narita, T., Maskey, E., Stanlie, A., Kremer, M., Typas, D., Lammers, M., Mailand, N., Nussenzweig, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.050 · Cited by 469
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R., Gottipati, P., Muschel, R. J., Beech, J., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.005 · Cited by 430
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 417
Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
Yazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Zhou, J., Li, X., Wu, X., Zhang, T., Zhu, Q., Wang, X., Wang, H., Wang, K., Lin, Y., & Wang, X. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0479 · Cited by 386
Self-citationZhu, X., Shen, H., Yin, X., Yang, M., Wei, H., Chen, Q., Feng, F., Liu, Y., Xu, W., & Li, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1095-1 · Cited by 374
Self-citationRay-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.005 · Cited by 365
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., & Inui, K.-I. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110346 · Cited by 344
Rondinelli, B., Gogola, E., Yücel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P. A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3626 · Cited by 332
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Jiang, Z., Lim, S.-O., Yan, M., Hsu, J. L., Yao, J., Wei, Y., Chang, S.-S., Yamaguchi, H., Lee, H.-H., Ke, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139434 · Cited by 325
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene
Zhang, X., George, J., Deb, S., Degoutin, J. L., Takano, E. A., Fox, S. B., AOCS Study group, Bowtell, D. D. L., & Harvey, K. F. (2011) · Oncogene · doi:10.1038/onc.2011.8 · Cited by 309
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., Zhuang, W., Li, L., & Tao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01442-3 · Cited by 292
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M., Shih, I.-M., Wang, T.-L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 290
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
The roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
Clarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280
Hayakawa, J., Ohmichi, M., Kurachi, H., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., & Murata, Y. (2000) · PubMed · Cited by 274
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 265
Self-citationHippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Hall, C. A., Wang, R., Miao, J., Oliva, E., Shen, X., Wheeler, T., Hilsenbeck, S. G., Orsulic, S., & Goode, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1242 · Cited by 263
Parikh, A., Lee, C., Joseph, P., Marchini, S., Baccarini, A., Kolev, V., Romualdi, C., Fruscio, R., Shah, H., Wang, F., et al. (2014) · Nature Communications · doi:10.1038/ncomms3977 · Cited by 258
MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer
Bhattacharya, R., Nicoloso, M., Arvizo, R., Wang, E., Cortez, A., Rossi, S., Calin, G. A., & Mukherjee, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2552 · Cited by 240
The ATM Kinase Induces MicroRNA Biogenesis in the DNA Damage Response
Zhang, X., Wan, G., Berger, F. G., He, X., & Lu, X. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.01.020 · Cited by 239
Richardson, D. L., Eskander, R. N., & O’Malley, D. M. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0197 · Cited by 226
Xiang, Y., Ma, N., Wang, D., Zhang, Y., Zhou, J., Wu, G., Zhao, R., Huang, H., Wang, X., Qiao, Y., et al. (2014) · Oncogene · doi:10.1038/onc.2012.575 · Cited by 225
Self-citationKonstantinopoulos, P. A., Cheng, S.-C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L. R., Crispens, M. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30180-7 · Cited by 225
lzquierdo, M. A., Zee, A. G. J. V. D., Vermorken, J. B., Valk, P. V. D., Belien, J. A. M., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.16.1230 · Cited by 220
Kanlikilicer, P., Bayraktar, R., Denizli, M., Rashed, M. H., Ivan, C., Aslan, B., Mitra, R., Karagoz, K., Bayraktar, E., Zhang, X., et al. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.11.004 · Cited by 220
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
He, Y. J., Meghani, K., Caron, M.-C., Yang, C., Ronato, D. A., Bian, J., Sharma, A., Moore, J., Niraj, J., Detappe, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0670-5 · Cited by 219
Srivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421365112 · Cited by 188 · cited 2×
“It increases the tolerance of tumor cells to plat-inum-induced DNA adducts and results in platinum resistance [92].”
BackgroundMcAlpine, J. N., Porter, H., Köbel, M., Nelson, B. H., Prentice, L. M., Kalloger, S. E., Senz, J., Milne, K., Ding, J., Shah, S. P., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.211 · Cited by 185
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Tagde, P., Ahmed, Z., Khan, F. S., et al. (2022) · Life · doi:10.3390/life12060897 · Cited by 181
Marchini, S., Fruscio, R., Clivio, L., Beltrame, L., Porcu, L., Nerini, I. F., Cavalieri, D., Chiorino, G., Cattoretti, G., Mangioni, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.026 · Cited by 176
Su, H., Lai, H., Lin, Y., Liu, C., Chen, C., Chou, Y., Lin, S., Lin, W., Lee, H., & Yu, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25083 · Cited by 176
TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer
Zhang, S.-F., Wang, X.-Y., Fu, Z.-Q., Peng, Q.-H., Zhang, J.-Y., Ye, F., Fu, Y.-F., Zhou, C.-Y., Lu, W.-G., Cheng, X.-D., et al. (2015) · Autophagy · doi:10.1080/15548627.2014.998931 · Cited by 171
Self-citationmiR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
Sun, C., Li, N., Yang, Z., Zhou, B., He, Y., Weng, D., Fang, Y., Wu, P., Chen, P., Yang, X., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt302 · Cited by 169
Minireview: Epigenetic Changes in Ovarian Cancer
Balch, C., Fang, F., Matei, D. E., Huang, T. H. ‐., & Nephew, K. P. (2009) · Endocrinology · doi:10.1210/en.2009-0404 · Cited by 162
Miyamoto, T., Murakami, R., Hamanishi, J., Tanigaki, K., Hosoe, Y., Mise, N., Takamatsu, S., Mise, Y., Ukita, M., Taki, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0407 · Cited by 161
Hu, S., Yu, L., Li, Z., Shen, Y., Wang, J., Cai, J., Xiao, L., & Wang, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.8.12913 · Cited by 159
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
Huang, T.-T., Lampert, E. J., Coots, C., & Lee, J.-M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102021 · Cited by 159
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
Tanaka, M., & Siemann, D. W. (2020) · Cancers · doi:10.3390/cancers12071850 · Cited by 158
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Wilson, C., Ye, X., Pham, T., Lin, E., Chan, S., McNamara, E., Neve, R. M., Belmont, L., Koeppen, H., Yauch, R. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1009 · Cited by 150
Choi, Y. E., Meghani, K. A., Brault, M. E., Leclerc, L., He, Y. J., Day, T. A., Elias, K. M., Drapkin, R., Weinstock, D. M., Dao, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.046 · Cited by 149
Wang, Y., Wang, Y., Qin, Z., Cai, S., Yu, L., Hu, H., & Zeng, S. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1887139 · Cited by 145
Self-citationNF-κB Signaling in Ovarian Cancer
Harrington, B. S., & Annunziata, C. M. (2019) · Cancers · doi:10.3390/cancers11081182 · Cited by 140
Lheureux, S., Oaknin, A., Garg, S., Bruce, J. P., Madariaga, A., Dhani, N. C., Bowering, V. L., White, J., Accardi, S., Tan, D. S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4121 · Cited by 138
MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition
Wang, Y., Huang, J., Calses, P. C., Kemp, C. J., & Taniguchi, T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0103 · Cited by 137
Self-citationLukanović, D., Herzog, M., Kobal, B., & Černe, K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110401 · Cited by 135
Liu, G., Yang, D., Rupaimoole, R., Pecot, C. V., Sun, Y., Mangala, L. S., Li, X., Ji, P., Cogdell, D. E., Hu, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv108 · Cited by 134
Self-citationHsu, K.-F., Shen, M.-R., Yf, H., Cheng, Y.-M., Lin, S.-H., Chow, N.-H., Cheng, S.-W., Chou, C., & Ho, C.-L. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.254 · Cited by 133
Liu, J. F., Moore, K. N., Birrer, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw401 · Cited by 132
Kaye, S. B., Fehrenbacher, L., Holloway, R. W., Amit, A., Karlan, B. Y., Slomovitz, B. M., Sabbatini, P. J., Fu, L., Yauch, R. L., Chang, I., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1796 · Cited by 131
González-Martín, A., Pothuri, B., Vergote, I. B., Graybill, W. A. S., Lorusso, D., McCormick, C., Freyer, G., Backes, F. J., Heitz, F., Redondo, A., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.024 · Cited by 130
YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma
Omori, H., Nishio, M., Masuda, M., Miyachi, Y., Ueda, F., Nakano, T., Sato, K., Mimori, K., Taguchi, K., Hikasa, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay3324 · Cited by 129
Samimi, G., Fink, D. A., Varki, N. M., Husain, A., Hoskins, W. J., Alberts, D. S., & Howell, S. B. (2000) · PubMed · Cited by 128
Santiskulvong, C., Konecny, G. E., Fekete, M., Chen, K.-Y. M., Karam, A., Mulholland, D. J., Eng, C., Wu, H., Song, M., & Dorigo, O. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2289 · Cited by 128
Jo, U., Senatorov, I. S., Zimmermann, A., Saha, L. K., Murai, Y., Kim, S. H., Rajapakse, V. N., Elloumi, F., Takahashi, N., Schultz, C. W., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1026 · Cited by 128
Bram, E. E., Stark, M., Raz, S., & Assaraf, Y. G. (2009) · Neoplasia · doi:10.1593/neo.91314 · Cited by 126
Jeong, J.-Y., Kang, H., Kim, T. H., Kim, G., Heo, J. H., Kwon, A., Kim, S., Jung, S. G., & An, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.017 · Cited by 126
Memory for temporal order and conditional associative-learning in patients with Parkinson's disease
Vriezen, E. R., & Moscovitch, M. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90044-o · Cited by 125
Antony, J., Tan, T. Z., Kelly, Z., Low, J. J. H., Choolani, M. A., Recchi, C., Gabra, H., Thiery, J. P., & Huang, R. Y. (2016) · Science Signaling · doi:10.1126/scisignal.aaf8175 · Cited by 125
Dilawari, A. A., Shah, M., Ison, G., Gittleman, H. R., Fiero, M. H., Shah, A. B., Hamed, S. S., Qiu, J., Yu, J., Manheng, W., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0991 · Cited by 124
Burger, H., Zoumaro-Djayoon, A. D., Boersma, A., Helleman, J., Berns, E., Mathijssen, R. H. J., Loos, W., & Wiemer, E. A. C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00569.x · Cited by 122
Beretta, G. L., Benedetti, V., Cossa, G., Assaraf, Y. G., Bram, E. E., Gatti, L., Corna, E., Carenini, N., Colangelo, D., Howell, S. B., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.002 · Cited by 122
Miyamoto, T., Murakami, R., Hamanishi, J., Tanigaki, K., Hosoe, Y., Mise, N., Takamatsu, S., Mise, Y., Ukita, M., Taki, M., et al. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.14989/doctor.k23801 · Cited by 112
Sakamoto, M., Kondo, A., Kawasaki, K., Goto, T., Sakamoto, H., Miyake, K., Koyamatsu, Y., Akiya, T., Iwabuchi, H., Muroya, T., et al. (2001) · PubMed · Cited by 110
Li, X., Chen, W., Jin, Y., Xue, R., Su, J., Mu, Z., Li, J., & Jiang, S. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.009 · Cited by 110
Abbosh, P. H., Montgomery, J. S., Starkey, J. A., Novotný, M. V., Zuhowski, E. G., Egorin, M. J., Moseman, A. P., Golas, A. A., Brannon, K. M., Balch, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3575 · Cited by 109
Mismatch repair and treatment resistance in ovarian cancer
Helleman, J., van Staveren, I. L., Dinjens, W. N. M., van Kuijk, P. F., Ruigrok-Ritstier, K., Ewing, P. C., van der Burg, M. E., Stoter, G., & Berns, E. M. J. J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-201 · Cited by 109
Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies
Kariolis, M. S., Miao, Y. R., Diep, A. N., Nash, S. E., Olcina, M. M., Jiang, D., Jones, D. S., Kapur, S., Mathews, I. I., Koong, A. C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85610 · Cited by 108
Cascio, S., Chandler, C., Zhang, L., Sinno, S., Gao, B., Onkar, S., Bruno, T. C., Vignali, D. A. A., Mahdi, H., Osmanbeyoglu, H. U., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi5790 · Cited by 107
Mo, Y., Leung, L. L., Mak, C. S. L., Wang, X., Chan, W.-S., Hui, L. M. N., Tang, H. W., Siu, M. K. Y., Sharma, R., Xu, D., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01703-9 · Cited by 107
Self-citationNesic, K., Kondrashova, O., Hurley, R. M., McGehee, C. D., Vandenberg, C. J., Ho, G., Lieschke, E., Dall, G., Bound, N. T., Shield‐Artin, K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0774 · Cited by 105
Zhang, T., Sun, B., Zhong, C., Xu, K., Wang, Z., Hofman, P. M., Nagano, T., Legras, A., Breadner, D. A., Ricciuti, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-303 · Cited by 102
Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., Borts, R. H., & Brown, R. E. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80047-5 · Cited by 100
Kanev, P.-B., Atemin, A., Stoynov, S., & Aleksandrov, R. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.001 · Cited by 99
Systematic Screen Identifies miRNAs That Target RAD51 and RAD51D to Enhance Chemosensitivity
Huang, J., Wang, Y., Dhillon, K. K., Calses, P. C., Villegas, E., Mitchell, P. S., Tewari, M., Kemp, C. J., & Taniguchi, T. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0292 · Cited by 97
Self-citationNF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
Devanaboyina, M., Kaur, J., Whiteley, E., Lin, L., Einloth, K. R., Morand, S. M., Stanbery, L., Hamouda, D., & Nemunaitis, J. J. (2022) · Oncology Reviews · doi:10.3389/or.2022.10568 · Cited by 97
Luo, X., Dong, Z., Chen, Y., Yang, L., & Lai, D. (2013) · Cell Proliferation · doi:10.1111/cpr.12038 · Cited by 96
Do, K. T., Kochupurakkal, B. S., Kelland, S., de Jonge, A., Hedglin, J., Powers, A., Quinn, N., Gannon, C., Vuong, L., Parmar, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1279 · Cited by 96
The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer
Yang, G. S., Xiao, X., Rosen, D. G., Cheng, X., Wu, X., Chang, B., Liu, G., Xue, F., Mercado‐Uribe, I., Chiao, P. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3265 · Cited by 93
Oza, A. M., Matulonis, U. A., Secord, A. A., Nemunaitis, J. J., Roman, L. D., Blagden, S. P., Banerjee, S. N., McGuire, W. P., Ghamande, S. A., Birrer, M. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1638 · Cited by 93
Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells
Kalayda, G. V., Wagner, C. H., & Jaehde, U. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.07.010 · Cited by 90
Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent
Fu, S., Naing, A., Fu, C., Kuo, M. T., & Kurzrock, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0864 · Cited by 90
Nishio, H., Yaguchi, T., Sugiyama, J., Sumimoto, H., Umezawa, K., Iwata, T., Susumu, N., Fujii, T., Kawamura, N., Kobayashi, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.251 · Cited by 86
van Jaarsveld, M. T. M., van Kuijk, P. F., Boersma, A. W. M., Helleman, J., van IJcken, W. F. J., Mathijssen, R. H. J., Pothof, J., Berns, E. M. J. J., Verweij, J., & Wiemer, E. A. C. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0464-4 · Cited by 86
Moore, K. N., Chambers, S. K., Hamilton, E. P., Chen, L.-M., Oza, A. M., Ghamande, S. A., Konecny, G. E., Plaxe, S. C., Spitz, D. L., Geenen, J. J. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0158 · Cited by 86
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer
Burdett, N. L., Willis, M. O., Alsop, K., Hunt, A. L., Pandey, A., Hamilton, P. T., Abulez, T. S., Liu, X., Hoang, T., Craig, S., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01320-2 · Cited by 86
Choi, Y. E., Pan, Y., Park, E., Konstantinopoulos, P. A., De, S., D’Andrea, A. D., & Chowdhury, D. (2014) · eLife · doi:10.7554/elife.02445 · Cited by 85
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Vescarelli, E., Gerini, G., Megiorni, F., Anastasiadou, E., Pontecorvi, P., Solito, L., Vitis, C. D., Camero, S., Marchetti, C., Mancini, R., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1490-7 · Cited by 85
Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
McCormick, A., Donoghue, P. S., Dixon, M., O'Sullivan, R., O'Donnell, R. L., Murray, J., Kaufmann, A., Curtin, N. J., & Edmondson, R. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0564 · Cited by 80
Bagratuni, T., Mavrianou, N., Gavalas, N. G., Tzannis, K., Arapinis, C., Liontos, M., Christodoulou, M., Thomakos, N., Haidopoulos, D. A., Rodolakis, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.017 · Cited by 79
miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer
Tan, H. L. E., He, Q., Gong, G., Wang, Y., Li, J., Wang, J., Zhu, D. L., & Wu, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3241 · Cited by 75
Self-citationMicroRNA‐mediated drug resistance in ovarian cancer
Mihanfar, A., Fattahi, A., & Nejabati, H. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26060 · Cited by 75
Sustained active site rigidity during synthesis by human DNA polymerase μ
Moon, A. F., Pryor, J. M., Ramsden, D. A., Kunkel, T. A., Bębenek, K., & Pedersen, L. C. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2766 · Cited by 74
Boušová, I., & Skálová, L. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.713969 · Cited by 74
Meghani, K. A., Fuchs, W., Detappe, A., Drané, P., Gogola, E., Rottenberg, S., Jonkers, J., Matulonis, U. A., Swisher, E. M., Konstantinopoulos, P. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.038 · Cited by 73
Park, G. B., & Kim, D. (2019) · Neoplasia · doi:10.1016/j.neo.2018.12.005 · Cited by 72
Structure–Function Studies of DNA Polymerase λ
Bębenek, K., Pedersen, L. C., & Kunkel, T. A. (2014) · Biochemistry · doi:10.1021/bi4017236 · Cited by 71
Nagaraj, A. B., Knarr, M., Sekhar, S. C., Connor, R. S., Joseph, P. L., Kovalenko, O., Fleming, A., Surti, A., Nurmemmedov, E., Beltrame, L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2041 · Cited by 71
LTAN, B., Yokobori, T., Ide, M., Bai, T., Yanoma, T., Kimura, A., Kogure, N., Suzuki, M., Bao, P., Mochiki, E., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11094 · Cited by 70
Recent advancements of antiangiogenic combination therapies in ovarian cancer
An, D., Banerjee, S. N., & Lee, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102224 · Cited by 70
Borley, J., & Brown, R. E. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1043140 · Cited by 69
Musa, F., Alard, A., David‐West, G., Curtin, J. P., Blank, S. V., & Schneider, R. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0926 · Cited by 69
MiR-337–3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB
Zhang, Z., Zhang, L., Wang, B., Wei, R., Wang, Y., Wan, J., Zhang, C., Zhao, L., Zhu, X., Zhang, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.021 · Cited by 69
Self-citationZou, Z., Zou, R., Zong, D., Shi, Y., Chen, J., Huang, J., Zhu, J., Chen, L., Bao, X., Liu, Y., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13114 · Cited by 67
Rahman, M. T., Nakayama, K., Rahman, M., Katagiri, H., Katagiri, A., Ishibashi, T., Ishikawa, M., Iida, K., Nakayama, S., Otsuki, Y., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpkdlrq8f3ewns · Cited by 66
Zou, W., MA, X., Wei, H., Chen, B., & CAI, G. (2015) · Oncology Reports · doi:10.3892/or.2015.4320 · Cited by 65
MicroRNAs, DNA Damage Response, and Cancer Treatment
He, M., Zhou, W., Li, C., & Guo, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122087 · Cited by 65
Matei, D. E., Ghamande, S. A., Roman, L. D., Secord, A. A., Nemunaitis, J. J., Markham, M. J., Nephew, K. P., Jueliger, S., Oganesian, A., Naim, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3055 · Cited by 65
Colombo, N., Tomao, F., Panici, P. B., Nicoletto, M. O., Tognon, G., Bologna, A., Lissoni, A. A., DeCensi, A., Lapresa, M., Mancari, R., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.015 · Cited by 65
TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity
Ali, S., Rehman, M. U., Yatoo, A. M., Arafah, A. M., Khan, A., Rashid, S., Majid, S., Ali, A., & Ali, M. N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175678 · Cited by 64
Zhou, Y., Chen, Q., Qin, R., Zhang, K., & Li, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2551-3 · Cited by 63
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis
Shen, J., Liang, C., Su, X., Wang, Q., Ke, Y., Fang, J., Zhang, D., & Duan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00419-8 · Cited by 63
Mullen, M. M., Lomonosova, E., Toboni, M. D., Oplt, A., Cybulla, E., Blachut, B., Zhao, P., Noia, H. M., Wilke, D., Rankin, E. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0302 · Cited by 62
Koti, M., Siu, A., Clément, I., Bidarimath, M., Turashvili, G., Edwards, A. K., Rahimi, K., Mes‐Masson, A., & Squire, J. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.459 · Cited by 60
Liu, J. F., Burris, H. A., Wang, J. S.-Z., Barroilhet, L. M., Gutierrez, M. E., Wang, Y., Vaze, A., Commerford, R., Royer‐Joo, S., Choeurng, V., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.09.023 · Cited by 58
Self-citationKoti, M., Siu, A., Clément, I., Bidarimath, M., Turashvili, G., Edwards, A., Rahimi, K., Masson, A.-M. M., & Squire, J. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.81 · Cited by 57
Burkitt, K., & Ljungman, M. E. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-24 · Cited by 57
Jiang, B., Zhu, S., Xiao, S., & Xue, M. (2019) · Inflammation · doi:10.1007/s10753-019-01004-2 · Cited by 56
Role of Epigenomics in Ovarian and Endometrial Cancers
Balch, C., Matei, D. E., Huang, T. H. ‐., & Nephew, K. P. (2010) · Epigenomics · doi:10.2217/epi.10.19 · Cited by 55
Embaby, A., Kutzera, J., Geenen, J. J. J., Pluim, D., Hofland, I., Sanders, J., López‐Yurda, M., Beijnen, J. H., Huitema, A. D. R., Witteveen, P. O., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.05.063 · Cited by 55
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
Doo, D. W., Meza‐Perez, S., Londoño, A. I., Goldsberry, W. N., Katre, A. A., Boone, J. D., Moore, D. J., Hudson, C. T., Betella, I., McCaw, T. R., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920913798 · Cited by 53
The evolving landscape of antibody-drug conjugates in gynecologic cancers
Tolcher, A. W., Hamilton, E. P., & Coleman, R. L. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102546 · Cited by 53
Iba, T., Kigawa, J., Kanamori, Y., Itamochi, H., Oishi, T., SHIMADA, M., Uegaki, K., Naniwa, J., & Terakawa, N. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03225.x · Cited by 52
Newsted, D., Banerjee, S., Watt, K., Nersesian, S., Truesdell, P. F., Blazer, L. L., Cardarelli, L., Adams, J., Sidhu, S. S., & Craig, A. W. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1539613 · Cited by 51
Fix, S. M., Forget, M., Sakellariou-Thompson, D., Wang, Y., Griffiths, T., Lee, M., Haymaker, C., Dominguez, A. L., Başar, R., Reyes, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003750 · Cited by 51
Self-citationLoss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis
Lum, E., Vigliotti, M., Banerjee, N., Cutter, N. L., Wrzeszczyński, K. O., Khan, S. A., Kamalakaran, S., Levine, D. A., Dimitrova, N., & Lucito, R. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.002 · Cited by 50
Lee, S., Yoon, S., & Kim, D. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.040 · Cited by 47
LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1
Shi, C., & Wang, M. (2018) · Medical Science Monitor · doi:10.12659/msm.910932 · Cited by 47
Coleman, R. L., Handley, K. F., Burger, R. A., Molin, G. Z. D., Stagg, R., Sood, A. K., & Moore, K. N. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.042 · Cited by 46
Tsuda, N., Kawano, K., Efferson, C. L., & Ioannides, C. G. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.5.1299 · Cited by 45
Yi, H., Liu, L., Sheng, N., Li, P., Pan, H., Cai, L., & Ma, Y. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b00141 · Cited by 45
Mesquita, K. A., Alabdullah, M., Griffin, M., Toss, M. S., Fatah, T. M. A. A., Alblihy, A., Moseley, P. M., Chan, S. Y. T., Rakha, E. A., & Madhusudan, S. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.02.014 · Cited by 45
miR-340: A multifunctional role in human malignant diseases
Huang, Z., Xu, Y., Wan, M., Zeng, X., & Wu, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.51123 · Cited by 45
Chan, D. W., Lam, W.-Y., Chen, F., Yung, M. M. H., Chan, Y.-S., Chan, W.-S., He, F., Liu, S. S., Chan, K. K. L., Li, B. C., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01130-5 · Cited by 45
Fang, X., Li, Y., Wan, Y., & Xue, M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3548-1 · Cited by 44
Rashid, K., Ahmad, A., Li, L., Liu, M., Cui, Y., & Liu, T. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.004 · Cited by 44
Santin, A. D., Vergote, I. B., González-Martı́n, A., Moore, K. N., Oaknin, A., Romero, I., Diab, S., Copeland, L. J., Monk, B. J., Coleman, R. L., et al. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003927 · Cited by 44
Muñoz-Galván, S., Felipe‐Abrio, B., García-Carrasco, M., Domínguez-Piñol, J., Suárez-Martínez, E., Verdugo‐Sivianes, E. M., Espinosa-Sánchez, A., Navas, L. E., Otero-Albiol, D., Marín, J., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1245-5 · Cited by 43
Wang, N., Yan, Y., Jin, D., Zhang, Z., Shen, K., Yang, J., Chen, H., Zhao, X., Li, Y., & Lu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967633 · Cited by 42
P‐Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer
Stage, T. B., Mortensen, C., Khalaf, S., Steffensen, V., Hammer, H., Xiong, C., Nielsen, F., Poetz, O., Svenningsen, Å. F., Rodríguez‐Antona, C., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1847 · Cited by 40
Guyon, N., Garnier, D., Briand, J., Nadaradjane, A., Bougras-Cartron, G., Raimbourg, J., Campone, M., Heymann, D., Vallette, F. M., Frenel, J., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03224-z · Cited by 40
Ovejero-Sánchez, M., González‐Sarmiento, R., & Herrero, A. B. (2023) · Cancers · doi:10.3390/cancers15020448 · Cited by 39
Lee, J., Chae, J.-W., Kim, J. K., Kim, H. J., Chung, J. Y., & Kim, Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.015 · Cited by 38
Wei, L., He, Y., Bi, S., Li, X., Zhang, J., & Zhang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7895 · Cited by 38
Epi‐miRNAs : Modern mediators of methylation status in human cancers
Papadimitriou, M., Panoutsopoulou, K., Pilala, K., Scorilas, A., & Avgeris, M. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1735 · Cited by 38
Nguyen, H. T., Phung, C. D., Tran, T. H., Pham, T. T., Pham, L. M., Nguyen, T. T., Jeong, J., Choi, H., Ku, S., Yong, C. S., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.034 · Cited by 37
Fuh, K. C., Bookman, M. A., Liu, J. F., Coleman, R. L., Herzog, T. J., Thaker, P. H., Monk, B. J., Anderson, R., McIntyre, G., Rangwala, R. A., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.020 · Cited by 37
Hong, L., Wang, Y., Chen, W., & Yang, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27052 · Cited by 36
Self-citationPRKRA /PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
Hisamatsu, T., McGuire, M. H., Wu, S. Y., Rupaimoole, R., Pradeep, S., Bayraktar, E., Noh, K., Hu, W., Hansen, J. M., Lyons, Y., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1050 · Cited by 34
Yoshida, K., Yokoi, A., Sugiyama, M., Oda, S., Kitami, K., Tamauchi, S., Ikeda, Y., Yoshikawa, N., Nishino, K., Niimi, K., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01595-3 · Cited by 34
Deng, M., Wu, D., Zhang, Y., Jin, Z., & Miao, J. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.013 · Cited by 33
miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy
Zhou, Y., Wang, C., Ding, J., Chen, Y., Sun, Y., & Cheng, Z. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02412-x · Cited by 33
Diao, B., Sun, C., Yu, P., Zhao, Z., & Yang, P. (2023) · The FASEB Journal · doi:10.1096/fj.202300306r · Cited by 33
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers
Liptay, M., Barbosa, J. S., & Rottenberg, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00670 · Cited by 32
MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy
Cai, Y., An, B., Yao, D., Zhou, H., & Zhu, J. (2021) · Bioengineered · doi:10.1080/21655979.2021.2001989 · Cited by 32
miRNA-Dependent Regulation of AKT1 Phosphorylation
Frederick, M. I., Siddika, T., Zhang, P., Balasuriya, N., Turk, M., O’Donoghue, P., & Heinemann, I. U. (2022) · Cells · doi:10.3390/cells11050821 · Cited by 31
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Morosi, L., Matteo, C., Ceruti, T., Giordano, S., Ponzo, M., Frapolli, R., Zucchetti, M., Davoli, E., D’Incalci, M., & Ubezio, P. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41395 · Cited by 30
Li, S., Wu, Y., Zhang, J., Sun, H., & Wang, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266541 · Cited by 30
Self-citationEnhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation
Sun, S., Zhao, S., Yang, Q., Wang, W., Cai, E., Wen, Y., Yu, L., Wang, Z., & Cai, J. (2018) · Cancer Science · doi:10.1111/cas.13599 · Cited by 29
MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers
Srinivasan, G., Williamson, E. A., Kong, K., Jaiswal, A. S., Huang, G., Kim, H.-S., Schärer, O., Zhao, W., Burma, S., Sung, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903150116 · Cited by 28
The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
Yeo, X. H., Sundararajan, V., Wu, Z., Phua, Z. J. C., Ho, Y. Y., Peh, K. L. E., Chiu, Y.-C., Tan, T. Z., Kappei, D., Ho, Y. S., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05045-0 · Cited by 27
Wang, Y., Chen, Q., Wu, D., Chen, Q., Gong, G., He, L., & Wu, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04074-z · Cited by 26
Self-citationParashar, D., Geethadevi, A., Mittal, S., McAlarnen, L. A., George, J., Kadamberi, I. P., Gupta, P., Uyar, D. S., Hopp, E. E., Drendel, H. M., et al. (2022) · Cancers · doi:10.3390/cancers14040958 · Cited by 26
Kaźmierczak, D., Jopek, K., Sterzyńska, K., Nowicki, M. O., Ruciński, M., & Januchowski, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010526 · Cited by 25
hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer
Ercoli, A., Ferrandina, G., Raspaglio, G., Marone, M., Maggiano, N., Mastro, P. D., Panici, P. B., Mancuso, S., & Scambia, G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690579 · Cited by 24
Akbarzadeh, M., Akbarzadeh, S., & Majidinia, M. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153158 · Cited by 23
Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation?
Marcelis, C., van der Putten, H. W. H. M., Tops, C. M. J., Lutgens, L. C. H. W., & Moog, U. (2001) · Familial Cancer · doi:10.1023/a:1013865323890 · Cited by 22
Rad50 promotes ovarian cancer progression through NF‐κB activation
Li, Y., Wang, S., Li, P., Li, Y., Liu, Y., Fang, H., Zhang, X., Liu, Z., & Kong, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17017 · Cited by 22
Metadata
- Authors
- Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., & Zou, D.
- Venue
- Molecular Cancer
- Published
- 2024-03-28
- Volume
- 23
- Issue
- 1
- Pages
- 66-66
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W4393275890
- Cited by
- 255
- References
- 225
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.